secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056786
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q1 revenue $215.4M (+17% YoY); reaffirms FY2026 guidance >$1B
--------------------------------------------------------------------------------

- Q1 net product revenue $215.4M, up 17% YoY; diluted EPS $0.55 vs $0.78 in Q1 2025.
- Reaffirmed FY2026 WAKIX net revenue guidance of $1.0B-$1.04B; on track for >$1B.
- R&D expenses $69.4M (+101%) due to $32M upfront license payments; net income declined to $32.5M.
- Filed patent infringement suit vs AET Pharma/Sandoz; acquired exclusive license to pitolisant patent expiring 2042.
- Appointed Peter Anastasiou COO and Glenn Reicin CFO; cash and investments $870.5M as of March 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/0001104659-26-056786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer